M
1.80
0.02 (1.12%)
| 前收盘价格 | 1.78 |
| 收盘价格 | 1.81 |
| 成交量 | 790,879 |
| 平均成交量 (3个月) | 1,464,482 |
| 市值 | 152,989,744 |
| 价格/销量 (P/S) | 77.32 |
| 股市价格/股市净资产 (P/B) | 4.96 |
| 52周波幅 | |
| 利润日期 | 12 Nov 2025 |
| 稀释每股收益 (EPS TTM) | -0.770 |
| 总债务/股东权益 (D/E MRQ) | 416.80% |
| 流动比率 (MRQ) | 4.66 |
| 营业现金流 (OCF TTM) | -33.87 M |
| 杠杆自由现金流 (LFCF TTM) | -19.45 M |
| 资产报酬率 (ROA TTM) | -41.29% |
| 股东权益报酬率 (ROE TTM) | -307.27% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Milestone Pharmaceuticals Inc. | 看跌 | 看跌 |
AIStockmoo 评分
0.6
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.63 |
|
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.71% |
| 机构持股比例 | 22.25% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Propel Bio Management, Llc | 30 Jun 2025 | 1,791,557 |
| Alta Fundamental Advisers Llc | 30 Jun 2025 | 1,398,977 |
| Bml Capital Management, Llc | 30 Jun 2025 | 1,136,091 |
| Simplify Asset Management Inc. | 30 Jun 2025 | 990,000 |
| Lion Point Capital, Lp | 30 Jun 2025 | 548,806 |
| Boxer Capital, Llc | 30 Sep 2024 | 309,007 |
| Valeo Financial Advisors, Llc | 30 Jun 2025 | 130,699 |
| Cascades Capital Asset Management, Llc | 30 Jun 2025 | 67,135 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合